Peptonic Medical enters collaboration agreement with ’1.6 & 2.6 Million Club’

Stockholm October 31, 2017 – Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has signed a collaboration and sponsorship agreement with ’1.6 & 2.6 Million Club’.

-          Peptonic Medical is a company focusing on women’s health and by this collaboration agreement we want to support research that can lead a better quality of life for women and more effective treatments of women specific diseases, says Johan Inborr, CEO of Peptonic Medcial. Generally, research and development within women’s health has had low priority. We want to change this.

-          We are pleased to enter this collaboration with Peptonic Medical, and that the Company wants to support our activities to improve the health and quality of life of women. These are important issues that need to get more attention and more resources, says Alexandra Charles von Hofsten, chair person of ’1.6 & 2.6 Million Club’.

In accordance with the collaboration agreement, Peptonic will support the work of the 1.6 & 2.6 Million Club financially. In return, Peptonic will be invited to participate in events and campaigns organised by the 1.6 & 2.6 Million Club. This agreement expires by the end of 2018 unless extended by mutual agreement.

For more information, please contact;

Johan Inborr, CEO

Mobile: +46 708 853 893

E-mail: johan.inborr@peptonicmedical.se 

About the 1.6 & 2.6 Million Club

The 1.6 Million Club is a non-profit women's health organization that was founded in 1998 by Alexandra Charles, president ever since. She was inspired by the cardiologist, Karin Schenck-Gustafsson, and gynaecology professor, Britt-Marie Landgren, who could both tell of just how male-dominated the field of research was, and how women were discriminated within the health care sector. With the purpose of improving and creating equal research and healthcare, and in order to spread objective information, the 1.6 Million Club was established. The name came about because at the time, there were 1.6 million women over 45 years of age in Sweden.

Ten years later, the 2.6 Million Club was established for younger women, from 25 years and upwards. The 1.6 and 2.6 Million Clubs share the same objective, and anybody over the age of 18 is welcome as a member in the association (including men).

For more information: www.1.6miljonerklubben.com.  

About Peptonic Medical

PEPTONIC Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.

VagiVital™ is a trademark of PEPTONIC Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.  

The pipeline of PEPTONIC Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

In July 2014, PEPTONIC Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.

For more information: www.peptonicmedical.com

About VagiVital™ 

VagiVital™ is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

PEPTONIC Medical plans to launch VagiVital™ as a non-prescription self-care product in 2018.